Daré Bioscience Announces Phase 3 Plans For Sildenafil Cream, 3.6%, In The Treatment Of Female Sexual Arousal Disorder; Daré's Sildenafil Cream Has The Potential To Receive The First FDA Approval For FSAD
Daré Bioscience Announces Phase 3 Plans For Sildenafil Cream, 3.6%, In The Treatment Of Female Sexual Arousal Disorder; Daré's Sildenafil Cream Has The Potential To Receive The First FDA Approval For FSAD
FSAD is clinically analogous to erectile dysfunction in men.
To date, there are no FDA-approved pharmacological treatments for FSAD; Daré's Sildenafil Cream has the potential to receive the first FDA approval for FSAD.
FSAD在臨床上類似於男性勃起功能障礙。
迄今爲止，尚無FDA批准的FSAD藥物治療；Daré的西地那非乳膏有可能獲得針對FSAD的首個FDA批准。
Market research estimates approximately 10 million women in the U.S. are distressed from experiencing symptoms associated with FSAD and are actively seeking solutions to improve their condition.
市場研究估計，美國約有1000萬女性因經歷與FSAD相關的症狀而感到困擾，並積極尋求改善其控件的解決方案。
SAN DIEGO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in innovation for the health and wellbeing of women, and its collaborator Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced plans for a Phase 3 study of Sildenafil Cream, 3.6%, an investigational topical cream formulation of sildenafil being developed as an on-demand treatment for female sexual arousal disorder (FSAD), reflecting U.S. Food and Drug Administration (FDA) feedback for safety and efficacy evaluations to support the indication of treatment of FSAD in premenopausal women.
聖迭戈，2024年12月16日（全球新聞通訊）——Daré Bioscience, Inc.（納斯達克：DARE），作爲女性健康和福祉創新的領導者，以及其合作者Strategic Science & Technologies, LLC（SST），一家位於麻薩諸塞州劍橋的新型局部藥物遞送公司，今天宣佈計劃進行一項關於3.6%西地那非乳膏的第三階段研究，這是一種正在開發中的西地那非局部乳膏製劑，作爲女性性喚起障礙（FSAD）的按需治療，反映了美國食品藥品監督管理局（FDA）對安全性和有效性評估的反饋，以支持在絕經前女性中治療FSAD的適應症。
譯文內容由第三人軟體翻譯。
